Release Date: 27/02/23 08:12 Summary: FY22 Investor Presentation Price Sensitive: Yes Download Document 4.94MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%